Table 2.
Proposed scoring scheme for diagnosis.
| Case Number |
Cytology Diagnosis |
Follow-up histology (or urine) | Test | Our Results |
||
|---|---|---|---|---|---|---|
| NM > 21pg | NE > 0.9 | NCMR > 0.5 | ||||
| 1 | Atypical | None | 1 | 1 | 0 | 1 |
| 2 | Atypical | Urothelial carcinoma in situ | 1 | 1 | 0 | 1 |
| 3 | Atypical | None | 0 | 0 | 0 | 0 |
| 4 | Atypical | Papillary urothelial carcinoma HG non-invasive |
1 | 1 | 0 | 1 |
| 5 | Atypical | Benign (inflammation) | 1 | 0 | 0 | 0 |
| 6 | Negative | (Negative) | 0 | 0 | 0 | 0 |
| 7 | Negativel | (Atypical) | 0 | 0 | 0 | 0 |
| 8 | Negative | None | 0 | 1 | 0 | 0 |
| 9 | Negative | (Negative) | 0 | 0 | 0 | 0 |
| 10 | Suspicious | HG urothelial carcinoma | 1 | 1 | 0 | 1 |
| 11 | Positive | HG urothelial carcinoma | 1 | 1 | 1 | 1 |
| 12 | Suspicious | HG urothelial carcinoma | 1 | 1 | 0 | 1 |
| 13 | Suspicious | Urothelial carcinoma in situ | 1 | 1 | 0 | 1 |
| 14 | Positive | Urothelial carcinoma in situ | 1 | 1 | 1 | 1 |
| 15 | Suspicious | (Suspicious) | 1 | 1 | 1 | 1 |
| 16 | Positive | (Positive) | 1 | 1 | 1 | 1 |
| 17 | Positive | HG urothelial carcinoma | 1 | 1 | 1 | 1 |
| 18 | Positive | Ureter mass (developed metastastic bladder cancer) |
1 | 1 | 1 | 1 |
| 19 | Suspicious | HG urothelial carcinoma | 1 | 1 | 1 | 1 |
| 20 | Atypical | LG papillary urothelial carcinoma |
1 | 1 | 0 | 1 |
| 21 | Atypical | HG urothelial carcinoma | 1 | 1 | 0 | 1 |
| 22 | Atypical | HG urothelial carcinoma | 0 | 1 | 1 | 1 |
| 23 | Atypical | (Atypical) | 0 | 0 | 1 | 0 |
| 24 | Positive | HG urothelial carcinoma | 1 | 1 | 1 | 1 |
| 25 | Negative | None | 0 | 0 | 0 | 0 |
| 26 | Negative | None | 0 | 0 | 0 | 0 |
| 27 | Negative | None | 0 | 0 | 0 | 0 |
| 28 | Negative | None | 0 | 0 | 0 | 0 |
Abbreviations: NM = Nuclear mass, NE = Nuclear entropy, NCMR = Nuclear to cell mass ratio those with parenthesis only at the 3rd column indicate that only urine cytology follow-up is available.